In the latest quarter ending March 31, 2026, Enzon Pharmaceuticals consummated a merger with Viskase Companies, Inc., changing its corporate identity to Viskase Holdings, Inc. The transaction included a significant reverse stock split and the exchange of preferred stock for common equity. Post-merger, Enzon’s traditional pharmaceutical royalty revenues have largely ceased, with the company reporting minimal revenue and ongoing net losses reflecting legacy costs and restructuring activities. The operating pivot centers on integrating Viskase’s business in collagen casing manufacturing for the food industry, marking a sharp departure from Enzon’s past royalty-driven pharma model. While liquidity remains adequate with a current ratio above 2, elevated net debt poses financial discipline challenges. Governance changes and merger execution now shape the near-to-medium term outlook amid industry-specific competitive dynamics.